Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | MMEL1 | Q495T6 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21221264 | 0.93 | MME (0.59) | MMEACETDP1PAX8MMEL1 | |
| SCHEMBL21221262 | 0.93 | MME (0.59) | MMEACETDP1PAX8MMEL1 | |
| SCHEMBL21241434 | 0.90 | MME (0.52) | MMEACEMMEL1 | |
| SCHEMBL22398885 | 0.90 | MME (0.52) | MMEACEMMEL1 | |
| SCHEMBL18575929 | 0.83 | MME (0.60) | MMEACEMMEL1 | |
| SCHEMBL17164911 | 0.83 | MME (0.60) | MMEACEMMEL1 | |
| SCHEMBL1231410 | 0.82 | MME (0.54) | MMEACEMMEL1 | |
| SCHEMBL18576747 | 0.82 | MME (0.54) | MMEACEMMEL1 | |
| SCHEMBL597498 | 0.82 | MME (0.54) | MMEACEMMEL1 | |
| SCHEMBL21572792 | 0.82 | MME (0.54) | MMEACEMMEL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11426375-B2 | Substituted bisphenyl butanoic ester derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2022-08-30 | — | — | US | disclosed |
| US-20200246295-A1 | SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (CN) | 2020-08-06 | — | — | US | disclosed |
| US-10668035-B2 | Substituted bisphenyl butanoic ester derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2020-06-02 | — | — | US | disclosed |
| WO-2019154416-A1 | SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2019-08-15 | — | — | WO | disclosed |
| US-20190240177-A1 | SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (CN) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11426375-B2 | Substituted bisphenyl butanoic ester derivatives as NEP inhibitors | MME, REN, ECE1 | MME 1/4885ACE 4/4885TDP1 642/4885 |
| US-10668035-B2 | Substituted bisphenyl butanoic ester derivatives as NEP inhibitors | MME, REN, ECE1 | MME 1/4885ACE 4/4885TDP1 642/4885 |
| US-20200246295-A1 | SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS | MME, REN, ECE1 | MME 1/4885ACE 4/4885TDP1 642/4885 |
| US-20190240177-A1 | SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS | MME, REN, ECE1 | MME 1/4885ACE 4/4885TDP1 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.